New incident report
Incident Report Number: 2022-0524
Registrant Reference Number: 2021-CA-000233
Registrant Name (Full Legal Name no abbreviations): The Hartz Mountain Corporation
Address: 400 Plaza Drive
City: Secaucus
Prov / State: New Jersey
Country: USA
Postal Code: 07094-3688
Domestic Animal
Country: CANADA
Prov / State: BRITISH COLUMBIA
PMRA Registration No. 30733 PMRA Submission No. EPA Registration No.
Product Name: Hartz UltraGuard Flea and Tick Drops for Dogs 6 - 14 kg Spot-on
Yes
Unknown
Site: Animal / Usage sur un animal domestique
Animal's Owner
Dog / Chien
Chihuahua/Fox Terrier crossbred
1
Female
2
6.35
kg
Skin
Unknown / Inconnu
>30 min <=2 hrs / >30 min <=2 h
System
Unknown / Inconnu
No
No
Unknown/Inconnu
Treatment / Traitement
(eg. description of the frequency and severity of the symptoms
On 02-Sep-2021, a 2 year old, approximately 6.35 kilogram, neutered, female, Chihuahua/Fox Terrier (Unspecified) crossbred dog, in unknown condition, with no known concomitant medical condition, was administered 1 tube of Hartz UltraGuard Flea and Tick Drops for Dogs 6 - 14 kg (Phenothrin (Sumithrin)) via the topical route by the animal owner. Approximately 45 minutes post application, the dog developed hyperactivity and rolling (abnormal behaviour). Approximately 1 hour post application, the rolling resolved. The dog had not been evaluated by a veterinarian and no treatment had been performed. Bathing with liquid dish soap was recommended if the signs recurred or persisted. The dog was previously administered this product in Aug-2021 without issue, by the animal owner. No further information was received in this case.
Minor
The information contained in this report is based on self-reported statements provided to the registrant during telephone interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and cannot form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews.